Dr. Petrylak on Atezolizumab in Bladder Cancer

Partner | Cancer Centers | <b>Yale Cancer Center</b>

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti—PD-L1 antibody atezolizumab in bladder cancer.

In the phase I trial, it was demonstrated that patients that had high levels of PD-L1 staining in the immune cells, either 2+ or 3+, had a better survival than those patients who had 0-1+ PD-L1 levels, says Petrylak.

However, even those patients who had had 0-1+ PD-L1 levels, still benefited, with a median survival of eight months. The 2+/3+ patient group has not yet reached median survival, he adds.

This is an active drug in bladder cancer, says Petrylak.